Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin

References

• van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–662.
   PubMed Web of Science ®Google Scholar
• Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53–59.
   PubMed Web of Science ®Google Scholar
• Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(Suppl 1):35–42.
   PubMed Web of Science ®Google Scholar
• Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):CD007076.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Thomas ET, Lee JJ, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ OPEN. 2019;9(1):e023600.
   PubMed Web of Science ®Google Scholar
• NHS England. Handling of gabapentin and pregabalin as Schedule 3 Controlled Drugs in health and justice commissioned services: letter from Kate Davies Internet. London: Health & Justice, Armed Forces and Sexual Assault Referral Centres (SARCs); 2019. cited 2019 April 9. Available from: https://www.england.nhs.uk/publication/handling-of-gabapentin-and-pregabalin-as-schedule-3-controlled-drugs-in-health-and-justice-commissioned-services/
   Google Scholar
• NHS England. Rescheduling of gabapentin and pregabalin as schedule 3 controlled drugs: briefing note Internet. London: NHS England; 2019. cited 2019 April 9. Available from: https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Support%20alert/Pregabalin%20and%20Gabapentin%20Briefing%20Note%20-%2012%20Feb%202019%20(002).pdf?ver=2019-02-13-153122-913
   Google Scholar
• Stanos SP, Galluzzi KE. Topical therapies in the management of chronic pain. Postgrad Med. 2013;125(4 Suppl 1):25–33.
   PubMedGoogle Scholar
• Derry S, Wiffen PJ, Moore RA, et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;(7):CD010958.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions Internet. Version 5.1.0 updated March 2011: The Cochrane Collaboration; 2011. cited 2011 March 23. Available from: http://handbook.cochrane.org/.
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care. York: University of York; 2009. [cited 2011 March 23]. Available from: http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429–437.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials Internet 2011; last updated September 2016. [cited 2016 Dec 8]. Available from: http://www.nicedsu.org.uk
   Google Scholar
• Song F, Altman DG, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472.
   PubMed Web of Science ®Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8(1):33.
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663–1676.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. A study for treatment of pain in patients with diabetic neuropathy. NCT00785577. In: ClinicalTrials.gov Internet. Bethesda (MD): National Library of Medicine (US);2010. [cited 2018 Dec 18]. Available from: https://ClinicalTrials.gov/show/NCT00785577
   Google Scholar
• Jiang W, Ladd S, Martsberger C, et al. Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy. J Clin Psychopharmacol. 2011;31(2):207–213.
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–2110.
   PubMed Web of Science ®Google Scholar
• Mu Y, Liu X, Li Q, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized placebo-controlled trial. J Diabetes. 2018;10(3):256–265.
   PubMed Web of Science ®Google Scholar
• Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013;13(6):485–496.
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253–260.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628–638.
   PubMed Web of Science ®Google Scholar
• Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109–116.
   PubMed Web of Science ®Google Scholar
• Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12(2):203–213.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Duan WR, An G, et al. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain. 2015;156(10):2013–2020.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP, Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274–1283.
   PubMed Web of Science ®Google Scholar
• Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18(5):297–301.
   PubMed Web of Science ®Google Scholar
• Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute Herpes zoster. A double-blind and vehicle-controlled study. Reg Anesth Pain Med. 2008;33(4):320–325.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chen H, Xi L, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin for postherpetic neuralgia in a population of Chinese patients. Pain Pract. 2017;17(1):62–69.
   PubMed Web of Science ®Google Scholar
• Ogawa S, Suzuki M, Arakawa A, et al. Efficacy and tolerability of pregabalin for postherpetic neuralgia: a multicenter, randomized, double-blind, placebocontrolled clinical trial. J Japan Soc Pain Clinicians. 2010;17:141–152.
   Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39–44.
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109(1-2):26–35.
   PubMed Web of Science ®Google Scholar
• Stacey BR, Barrett JA, Whalen E, et al. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008;9(11):1006–1017.
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP, Jr, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22(2):375–384.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115(3):254–263.
   PubMed Web of Science ®Google Scholar
• Gilron I, Wajsbrot D, Therrien F, et al. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27(3):185–193.
   PubMed Web of Science ®Google Scholar
• Grünenthal GmbH. Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain. EudraCT 2011-002092-42. In: EU Clinical Trials Register (EUCTR) Internet. London: European Medicines Agency (EMA); 2011 [cited 2018 Nov 21]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002092-42
   Google Scholar
• Palladini M, Boesl I, Koenig S, et al. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebocontrolled trial. Curr Med Res Opin. 2019;35(5):757–766.
   PubMed Web of Science ®Google Scholar
• Penide L, Flores-Garnica L, Gomez Agraz JL, et al. Postincitional neuropathic chronic pain after abdominal surgery: comparation efectivity between lidocaine 5% patch vs oral pregabalin. Presented at European Anaesthesiology Congress, EUROANAESTHESIA 2012; 2012 June 9-12; Paris, France. Eur J Anaesthesiol. 2012;29(Suppl 50):202.
   Google Scholar
• Pickering G, Clermont-Ferrand C. d. Clinical Report: Impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery. A prospective, randomized, placebo controlled study in parallel groups. EudraCT 2015-005601-37 PDF provided by the Company. Clermont-Ferrand: CHU de Clermont-Ferrand; 2017.
   Google Scholar
• Sansone P, Passavanti MB, Fiorelli A, et al. Efficacy of the topical 5% lidocaine medicated plaster in the treatment of chronic post-thoracotomy neuropathic pain. Pain Manag. 2017;7(3):189–196.
   PubMed Web of Science ®Google Scholar
• Markman J, Resnick M, Greenberg S, et al. Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. J Neurol. 2018;265(12):2815–2824.
   PubMed Web of Science ®Google Scholar
• van Seventer R, Bach FW, Toth CC, et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol. 2010;17(8):1082–1089.
   PubMed Web of Science ®Google Scholar
• Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clin Ther. 2011;33(2):159–166.
   PubMed Web of Science ®Google Scholar
• Moon DE, Lee DI, Lee SC, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther. 2010;32(14):2370–2385.
   PubMed Web of Science ®Google Scholar
• Bischoff JM, Petersen M, Uceyler N, et al. Lidocaine patch (5%) in treatment of persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. Anesthesiology. 2013;119(6):1444–1452.
   PubMed Web of Science ®Google Scholar
• Cheville AL, Sloan JA, Northfelt DW, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer. 2009;17(4):451–460.
   PubMed Web of Science ®Google Scholar
• Demant DT, Lund K, Finnerup NB, et al. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. Pain. 2015;156(11):2234–2244.
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80(3):533–538.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Ho TW, Galer B, et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain. 2011;152(3):514–521.
   PubMed Web of Science ®Google Scholar
• Huffman C, Stacey BR, Tuchman M, et al. Efficacy and safety of pregabalin in the treatment of patients with painful diabetic peripheral neuropathy and pain on walking. Clin J Pain. 2015;31(11):946–958.
   PubMed Web of Science ®Google Scholar
• Jenkins TM, Smart TS, Hackman F, et al. Efficient assessment of efficacy in post-traumatic peripheral neuropathic pain patients: pregabalin in a randomized, placebo-controlled, crossover study. J Pain Res. 2012;5:243–250.
   PubMedGoogle Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106(1):151–158.
   PubMed Web of Science ®Google Scholar
• Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain. 2014;30(5):379–390.
   PubMed Web of Science ®Google Scholar
• Raskin P, Huffman C, Yurkewicz L, et al. Pregabalin in patients with painful diabetic peripheral neuropathy using an NSAID for other pain conditions: a double-blind crossover study. Clin J Pain. 2016;32(3):203–210.
   PubMed Web of Science ®Google Scholar
• Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393–408.
   PubMed Web of Science ®Google Scholar
• Song D, He A, Xu R, et al. Efficacy of pain relief in different postherpetic neuralgia therapies: a network meta-analysis. Pain Physician. 2018;21(1):19–32.
   PubMed Web of Science ®Google Scholar
• Dosenovic S, Jelicic Kadic A, Miljanovic M, et al. Interventions for neuropathic pain: an overview of systematic reviews. Anesth Analg. 2017;125(2):643–652.
   PubMed Web of Science ®Google Scholar
• Navez ML, Monella C, Bosl I, et al. 5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther. 2015;4(1):1–15.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167–184.
   PubMed Web of Science ®Google Scholar
• Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639–649.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68(7):900–918.
   PubMed Web of Science ®Google Scholar
• Khadem T, Stevens V. Therapeutic options for the treatment of postherpetic neuralgia: a systematic review. J Pain Pall Care Pharmacother. 2013;27(3):268–283.
   PubMedGoogle Scholar
• Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster: a review. Curr Med Res Opin. 2012;28(6):937–951.
   PubMed Web of Science ®Google Scholar
• Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand. 2011;123(5):295–309.
   PubMed Web of Science ®Google Scholar
• Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21-22):297–306.
   PubMed Web of Science ®Google Scholar
• Plested M, Budhia S, Gabriel Z. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review. BMC Neurol. 2010;10(1):116.
   PubMed Web of Science ®Google Scholar
• Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007;(2):CD004846.
   PubMed Web of Science ®Google Scholar
• Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91(5):1343–1350.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug administration. Drug approval package: lidoderm (lidocaine) patch (Application No.: 20-612) Internet. Silver Spring: FDA; 2005 [cited 2019 May 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20612.cfm
   Google Scholar